A Prospective Study of Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular Carcinoma
In this prospective study, 68Ga-PSMA integrated PET/MR imaging was applied for the diagnosis and staging of hepatocellular carcinoma (HCC). The detection and diagnostic performance of 68Ga-PSMA PET/MR for HCC was evaluated in comparison with the gold standard of puncture biopsy or postoperative pathology. The aim is to make up for the deficiency in FDG PET imaging in the diagnosis and staging of HCC.
⁃ Each subject must meet all the inclusion criteria to be eligible for the study.
• Subjects or their legal representatives are able to sign an informed consent form
• Subjects are committed to comply with the study procedures and cooperate with the implementation of the full study
• Subjects are 18 years of age or older, regardless of gender
• Subjects with high suspicion of HCC, or diagnosed HCC without tumour-related treatment (supporting evidence including serum AFP, MRI, CT and other imaging data and histopathology), and in good general condition
• Subjects intend to obtain pathological results by biopsy or surgical resection